We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance for Performance Enhanced Medicines

By Biotechdaily staff writers
Posted on 23 Jul 2002
A collaborative agreement has been announced for the joint discovery of performance enhanced medicines (PEMs), novel pharmaceutical products created by using advances in biology to identify applications of established drugs in new indications. More...
The companies involved are GeneFormatics, Inc. (San Diego, CA, USA) and Arakis, Ltd. (Essex, UK).

GeneFormatics is a drug discovery company employing proprietary structural and chemoproteomic technologies for the discovery of target-specific drugs, while Arakis is an emerging specialty-pharmaceutical company focusing on the development and commercialization of innovative, market-orientated therapeutic products.

Under the terms of the agreement, GeneFormatics will use its structural proteomics capabilities to identify and describe secondary biochemical functional sites. This information, combined with Arakis' proprietary know-how and databases, will be used to define and validate protein targets for joint development of PEMs as pharmaceutical products.

"We are pleased to enter into this collaboration with Arakis, which marks our first drug discovery agreement,” said Dr. John Chiplin, president and CEO of GeneFormatics. "Our proprietary structural and chemoproteomics technologies will be used to screen and validate annotations against Arakis' database of pharmacological targets for the development of performance enhanced medicines in select therapeutic areas.”

"Through a combination of biology, chemistry, and in silico technologies, we intend to identify and create enhanced therapies tailored to treat diseases more effectively,” said Dr. Ken Cunningham, CEO of Arakis.



Related Links:
GeneFormatics
Arakis

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Manual Pipetting Aid
Pipette Controllers macro
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.